<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-29642" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Substance-Induced Mood Disorders</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Revadigar</surname>
            <given-names>Neelambika</given-names>
          </name>
          <aff>Jawaharlal Nehru Medical College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <aff>Wellness Psychiatry P.C</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Neelambika Revadigar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikas Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>14</day>
          <month>11</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-29642.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Substance-induced disorders include, among other disorders, substance/medication-induced mental disorders. Substance/medication-induced mental disorders refer to depressive, anxiety, psychotic, or manic symptoms that occur as a physiological consequence of the use of substances of abuse or medications. It may occur during active use, intoxication, or withdrawal. This activity outlines the epidemiology, presentation, diagnosis, clinical evaluation, psychopathology, and treatment of substance/medication-induced mental disorders covering depression and bipolar by an interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Interpret the epidemiology of substance/medication-induced disorders.</p></list-item><list-item><p>Assess&#x000a0;the typical presentation of alcohol, cocaine, or opioid-induced mood disorders.</p></list-item><list-item><p>Evaluate&#x000a0;the treatment options for substance/medication-induced disorders.</p></list-item><list-item><p>Communicate&#x000a0;the importance of an interprofessional approach in treating patients with substance/medication-induced disorders.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29642&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29642">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-29642.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Although both illicit substances and iatrogenic medications are ingested with the impetus to alleviate mood, a substantial proportion of patients experience paradoxical affective disorders following the ingestion of said substances. Instead of the prosaic euphoria experienced while intoxicated&#x000a0;or the&#x000a0;subsequent day's hangover, some individuals become manic or enter into a state of depression. Mood disorders that precipitate only in association with substance use are specified as substance-induced. Affective disorders that can precipitate in the setting of substance use include both bipolar and related disorders and&#x000a0;depressive disorders.&#x000a0;These disorders were previously found within the nosological category of substance-induced mood disorders in DSM-IV. However,&#x000a0;in the current DSM, substance-induced is now a specifier for mood disorders. Depression and bipolar disorder frequently co-occur with substance use disorders and are prevalent in the general population.<xref ref-type="bibr" rid="article-29642.r1">[1]</xref><xref ref-type="bibr" rid="article-29642.r2">[2]</xref><bold>&#x000a0;</bold>This topic reflects on both substance-induced depressive disorder and substance-induced bipolar and related disorders and further elaborates on how they&#x000a0;can be distinguished from mood disorders that are comorbid with substance abuse disorders. For this topic, the designation of substance-induced mood disorders - although no longer a distinct category in DSM-V - represents both substance-induced depression and bipolar disorders.</p>
      </sec>
      <sec id="article-29642.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Substance-induced disorders may develop in the context of either&#x000a0;intoxication or withdrawal. Of the depressive episodes occurring in the general population, nearly half precipitate in the context of heavy alcohol use.<xref ref-type="bibr" rid="article-29642.r3">[3]</xref><xref ref-type="bibr" rid="article-29642.r4">[4]</xref><xref ref-type="bibr" rid="article-29642.r5">[5]</xref>&#x000a0;The next most frequently associated substances are cocaine and opioids, especially heroin. Iatrogenic substances can also induce pathological affective states. Such medications include&#x000a0;interferon, corticosteroids, digoxin, and antiepileptic drugs.<xref ref-type="bibr" rid="article-29642.r6">[6]</xref><xref ref-type="bibr" rid="article-29642.r7">[7]</xref>&#x000a0;Either class - substance or medication - can induce states of mania or depression.&#x000a0;Current theorists posit that the aforementioned substances alter neurotransmitter transmission within important neural circuits, such as the mesolimbic tract and Papez circuit.<xref ref-type="bibr" rid="article-29642.r8">[8]</xref>&#x000a0;Recent evidence has also revealed that genes increase diathesis for both substance use disorders as well as mood disorders.<xref ref-type="bibr" rid="article-29642.r9">[9]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-29642.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Current research estimates the lifetime prevalence of substance-induced depressive disorders between 0.26% and 1%.<xref ref-type="bibr" rid="article-29642.r10">[10]</xref><xref ref-type="bibr" rid="article-29642.r1">[1]</xref>&#x000a0;Of those with alcohol use disorder, it is estimated that 40-60% experience substance-induced depression.<xref ref-type="bibr" rid="article-29642.r5">[5]</xref><xref ref-type="bibr" rid="article-29642.r11">[11]</xref><xref ref-type="bibr" rid="article-29642.r12">[12]</xref>&#x000a0;Data gathered from outpatient participants with opioid use disorder reported that around 55% of these participants had substance-induced depression.<xref ref-type="bibr" rid="article-29642.r13">[13]</xref>&#x000a0;Of the individuals with major depression, 16.5% have an alcohol use disorder, and 18% have a drug use disorder. Additionally, data indicate that the lifetime prevalence of substance use disorders in bipolar I patients is 61%.<xref ref-type="bibr" rid="article-29642.r14">[14]</xref><bold>&#x000a0;</bold></p>
      </sec>
      <sec id="article-29642.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of substance-induced disorders remains a topic of ongoing discussion. Drug-induced mood symptoms precipitate changes in&#x000a0;cerebral&#x000a0;structures, such as the frontal cortex, nucleus accumbens, olfactory tubercle, hippocampus, amygdala, and hypothalamus.<xref ref-type="bibr" rid="article-29642.r15">[15]</xref>&#x000a0;Drug-induced mood symptoms involve alterations of serotonergic, dopaminergic, corticotropin-releasing factor, and neuropeptide Y neurotransmitter activity.<xref ref-type="bibr" rid="article-29642.r16">[16]</xref><xref ref-type="bibr" rid="article-29642.r17">[17]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-29642.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with substance-induced affective disorders present similarly to patients with independent mood disorders with or without comorbid substance use disorders. Thus, patients may endorse&#x000a0;sad mood, insomnia, feelings of guilt, suicidal ideation, psychomotor retardation, distractibility, hopelessness, helplessness, irritability, decreased libido, energy, or anorexia if depressed. In the setting of mania, the patient endorses grandiosity, distractibility, impulsivity, pressured speech, racing thoughts, sexual promiscuity, irritability, insomnia, and increased energy. The anamnesis of a patient experiencing a substance-induced affective disorder consists of&#x000a0;mood symptomatology&#x000a0;in direct temporal relation to the ingestion of the substance. These symptoms resolve following the cessation of severe intoxication or acute withdrawal (up to 1 month). Generally, severe intoxication produces symptoms consistent with mania or hypomania,&#x000a0;whereas&#x000a0;withdrawal manifests as symptoms of depression. Depressants (eg alcohol, sedative-hypnotics, analgesics, etc) may&#x000a0;induce states&#x000a0;of euphoria, decreased impulse control, or mood lability. This intoxication phase is then supplanted by a withdrawal phase, most notable for irritability, agitation, and dysphoria. Stimulant use (eg cocaine, amphetamines, etc) can mimic bipolar spectrum disorders by producing euphoria,&#x000a0;increased energy, anorexia, grandiosity, and paranoia.&#x000a0;Stimulant&#x000a0;withdrawal can cause anhedonia, apathy, depressed mood, and suicidal ideation.<xref ref-type="bibr" rid="article-29642.r9">[9]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-29642.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The substance-induced mood disorder mimics&#x000a0;its corresponding independent affective disorder. Thus, substance-induced depression follows diagnostic criteria used to evaluate for depressive disorders, and substance-induced bipolar disorder reflects that of bipolar spectrum disorders.&#x000a0;As implied&#x000a0;by the title substance-induced, either admission of the ingestion of a substance or a positive laboratory test is necessary for a valid diagnosis. Temporality is the easiest feature to differentiate an independent affective disorder from a substance-induced one.&#x000a0;As mentioned previously, symptoms of a substance-induced mood disorder resolve following the cessation of severe intoxication or acute withdrawal (up to 1 month).<xref ref-type="bibr" rid="article-29642.r14">[14]</xref> For substance-induced depressive disorder, the clinical picture is characterized by a depressed mood or a markedly diminished interest or pleasure in all spheres of life, and the symptomatology is corroborated with the history, physical examination, or laboratory findings. For the substance/medication-induced bipolar, the clinical picture is delineated by an elevated, expansive, or irritable mood, with or without depressed mood, or markedly diminished interest or pleasure in all spheres of life. Clinical evidence is corroborated by history, physical examination, or laboratory findings. Laboratory results, imaging, and a detailed history should rule out other etiologies of the ongoing affective disorder.&#x000a0;</p>
      </sec>
      <sec id="article-29642.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Implicit with the diagnosis of substance-induced mood disorder is the implication that the disorder should resolve spontaneously following the cessation of the inciting irritant. However, the severity of a substance-induced affective episode may necessitate the application of medication.&#x000a0;Clinical judgment, corroborated with proper history and collateral information, aids the clinician's decision whether to offer supportive care while observing the patient in a safe environment during the withdrawal period or treat the active affective disorder. Because of the relative safety of most antidepressants, some studies suggest the empiric application of antidepressants in the setting of depressive symptomatology and co-occurring substance use.<xref ref-type="bibr" rid="article-29642.r14">[14]</xref>&#x000a0;For manic episodes, guidelines recommend second-generation antipsychotics, such as quetiapine&#x000a0;or olanzapine, as they are faster acting than mood stabilizers.<xref ref-type="bibr" rid="article-29642.r18">[18]</xref><xref ref-type="bibr" rid="article-29642.r19">[19]</xref><xref ref-type="bibr" rid="article-29642.r20">[20]</xref>&#x000a0;The most essential feature of treatment should be the emphasis on abstinence from the inciting substance.&#x000a0;The treatment modality varies depending on the patient's preference for that substance.&#x000a0;</p>
      </sec>
      <sec id="article-29642.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Transient <bold>s</bold>ubstance-induced disorders may be differentiated from a primary psychiatric illness through observation during a period of abstinence with a temporal association of the intake of a substance. A family history of a primary psychiatric illness may also facilitate distinction. For substance-induced symptoms of mania, the differentiation may be more complex because of a high probability of temporal association or causality of mood symptoms after substance use.<xref ref-type="bibr" rid="article-29642.r9">[9]</xref><xref ref-type="bibr" rid="article-29642.r3">[3]</xref><xref ref-type="bibr" rid="article-29642.r4">[4]</xref></p>
      </sec>
      <sec id="article-29642.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>In theory, mood symptoms should diminish following a period of sobriety. Maintenance of abstinence is the most robust&#x000a0;prognosticative factor for subsequent episodes. Thus, invariably, factors that promote sobriety potentiate remission. Familial support, psychotherapy, financial stability, and medication compliance are all factors that promote sobriety. Reciprocally, settings that increase the risk of substance use are associated with poorer prognoses.&#x000a0;</p>
      </sec>
      <sec id="article-29642.s11" sec-type="Complications">
        <title>Complications</title>
        <p>The most significant complication looming over substance-induced mood disorders is suicide. Studies reveal that suicide attempts are more common in affective disorders that are substance-induced. One study estimated an almost 4-fold increased risk of suicide attempts&#x000a0;when the mood disorder precipitates in the setting of substance use.<xref ref-type="bibr" rid="article-29642.r21">[21]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-29642.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Considerations for deterrence and patient education for substance-induced mood disorders include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Refrain from the use of alcohol or illicit drugs.</p>
          </list-item>
          <list-item>
            <p>Avoid people or milieu that most likely trigger the use of alcohol or illicit drugs.</p>
          </list-item>
          <list-item>
            <p>Consider psychosocial interventions like AA and NA to promote recovery from alcohol and substance abuse.</p>
          </list-item>
          <list-item>
            <p>Discuss with a physician about any new medication prescribed by another physician because some medications can cause mania or depression.</p>
          </list-item>
          <list-item>
            <p>Contact a physician<bold>&#x000a0;</bold>if having concerns regarding over-the-counter medicines because some OTCs can augment the effects of other medications and may cause mania or depression.</p>
          </list-item>
          <list-item>
            <p>Eat a healthy diet, limit caffeine, and quit smoking.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Be aware of depression or mania that results after the initiation of substance use or use of medication, and discuss them with your primary care physician or psychiatrist.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-29642.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing substance-induced disorders disorder requires a multidisciplinary approach involving the patient, the patient&#x02019;s family, the physician, the nurse, and the therapist. Although substance-induced disorders (depression and bipolar) subside after the biological effects of the drug fade, vulnerable individuals can develop a full-blown major depressive disorder or bipolar disorder; without proper management, psychiatric and medical complications can be fatal.&#x000a0;</p>
        <p>In the emergency department, physicians and assigned nurses are responsible for coordinating the care, which includes the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Drug levels in the blood and or urine</p>
          </list-item>
          <list-item>
            <p>Monitor the patient for signs and symptoms of respiratory depression and cardiac arrhythmias.</p>
          </list-item>
          <list-item>
            <p>Administer benzodiazepines or antipsychotics for acute mania.</p>
          </list-item>
          <list-item>
            <p>Creatine phosphokinase to rule out rhabdomyolysis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Provide rehydration with normal saline</p>
          </list-item>
          <list-item>
            <p>Provide 1:1 for safety (suicide and injury to others)</p>
          </list-item>
          <list-item>
            <p>Consider involuntary status for imminent threats to self and others</p>
          </list-item>
          <list-item>
            <p>Physical restraints as the last result</p>
          </list-item>
          <list-item>
            <p>Consult an addiction specialist</p>
          </list-item>
        </list>
        <p>In the outpatient clinic, the physician and assigned nurse are responsible for the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Assure the patient&#x02019;s safety and others in case of acute mania or severe depression.</p>
          </list-item>
          <list-item>
            <p>Transport the patient to the emergency department.</p>
          </list-item>
          <list-item>
            <p>Consider an involuntary commitment to a psychiatric hospital for imminent threats to self and others.</p>
          </list-item>
        </list>
        <p>Physicians, nurses, and therapists should discuss and involve the family in the treatment plan. An interprofessional team with a holistic and integrated approach can help achieve the best possible outcomes.&#x000a0;</p>
      </sec>
      <sec id="article-29642.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=29642&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=29642">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/mental-health/substance-induced-mood-disorders/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=29642">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/29642/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=29642">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-29642.s15">
        <title>References</title>
        <ref id="article-29642.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grant</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Stinson</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Dufour</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Compton</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Pickering</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.</article-title>
            <source>Arch Gen Psychiatry</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>61</volume>
            <issue>8</issue>
            <fpage>807</fpage>
            <page-range>807-16</page-range>
            <pub-id pub-id-type="pmid">15289279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tolliver</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Anton</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Assessment and treatment of mood disorders in the context of substance abuse.</article-title>
            <source>Dialogues Clin Neurosci</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <page-range>181-90</page-range>
            <pub-id pub-id-type="pmid">26246792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Inaba</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Gillin</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Schuckit</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Irwin</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Alcoholism and affective disorder: clinical course of depressive symptoms.</article-title>
            <source>Am J Psychiatry</source>
            <year>1995</year>
            <month>Jan</month>
            <volume>152</volume>
            <issue>1</issue>
            <fpage>45</fpage>
            <page-range>45-52</page-range>
            <pub-id pub-id-type="pmid">7802119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davidson</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis of depression in alcohol dependence: changes in prevalence with drinking status.</article-title>
            <source>Br J Psychiatry</source>
            <year>1995</year>
            <month>Feb</month>
            <volume>166</volume>
            <issue>2</issue>
            <fpage>199</fpage>
            <page-range>199-204</page-range>
            <pub-id pub-id-type="pmid">7728364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schuckit</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Danko</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Pierson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Trim</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nurnberger</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kuperman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bierut</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Hesselbrock</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>A comparison of factors associated with substance-induced versus independent depressions.</article-title>
            <source>J Stud Alcohol Drugs</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>68</volume>
            <issue>6</issue>
            <fpage>805</fpage>
            <page-range>805-12</page-range>
            <pub-id pub-id-type="pmid">17960298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patten</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Barbui</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced depression: a systematic review to inform clinical practice.</article-title>
            <source>Psychother Psychosom</source>
            <year>2004</year>
            <season>Jul-Aug</season>
            <volume>73</volume>
            <issue>4</issue>
            <fpage>207</fpage>
            <page-range>207-15</page-range>
            <pub-id pub-id-type="pmid">15184715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anisman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kokkinidis</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Merali</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Further evidence for the depressive effects of cytokines: anhedonia and neurochemical changes.</article-title>
            <source>Brain Behav Immun</source>
            <year>2002</year>
            <month>Oct</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>544</fpage>
            <page-range>544-56</page-range>
            <pub-id pub-id-type="pmid">12401468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Markou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kosten</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Koob</surname>
                <given-names>GF</given-names>
              </name>
            </person-group>
            <article-title>Neurobiological similarities in depression and drug dependence: a self-medication hypothesis.</article-title>
            <source>Neuropsychopharmacology</source>
            <year>1998</year>
            <month>Mar</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>135</fpage>
            <page-range>135-74</page-range>
            <pub-id pub-id-type="pmid">9471114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quello</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Sonne</surname>
                <given-names>SC</given-names>
              </name>
            </person-group>
            <article-title>Mood disorders and substance use disorder: a complex comorbidity.</article-title>
            <source>Sci Pract Perspect</source>
            <year>2005</year>
            <month>Dec</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-21</page-range>
            <pub-id pub-id-type="pmid">18552741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blanco</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Alegr&#x000ed;a</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Secades-Villa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sugaya</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nunes</surname>
                <given-names>EV</given-names>
              </name>
            </person-group>
            <article-title>Differences among major depressive disorder with and without co-occurring substance use disorders and substance-induced depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>73</volume>
            <issue>6</issue>
            <fpage>865</fpage>
            <page-range>865-73</page-range>
            <pub-id pub-id-type="pmid">22480900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gilder</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Wall</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Ehlers</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Comorbidity of select anxiety and affective disorders with alcohol dependence in southwest California Indians.</article-title>
            <source>Alcohol Clin Exp Res</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>12</issue>
            <fpage>1805</fpage>
            <page-range>1805-13</page-range>
            <pub-id pub-id-type="pmid">15608596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hesselbrock</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Easton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bucholz</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Schuckit</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hesselbrock</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>A validity study of the SSAGA--a comparison with the SCAN.</article-title>
            <source>Addiction</source>
            <year>1999</year>
            <month>Sep</month>
            <volume>94</volume>
            <issue>9</issue>
            <fpage>1361</fpage>
            <page-range>1361-70</page-range>
            <pub-id pub-id-type="pmid">10615721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmadi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Majdi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mahdavi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mohagheghzadeh</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Mood disorders in opioid-dependent patients.</article-title>
            <source>J Affect Disord</source>
            <year>2004</year>
            <month>Oct</month>
            <day>01</day>
            <volume>82</volume>
            <issue>1</issue>
            <fpage>139</fpage>
            <page-range>139-42</page-range>
            <pub-id pub-id-type="pmid">15465588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Myrick</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cluver</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Swavely</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of co-occurring affective disorders and substance use disorders.</article-title>
            <source>Psychiatr Clin North Am</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>649</fpage>
            <page-range>649-59</page-range>
            <pub-id pub-id-type="pmid">15550285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peroutka</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Snyder</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding.</article-title>
            <source>Science</source>
            <year>1980</year>
            <month>Oct</month>
            <day>03</day>
            <volume>210</volume>
            <issue>4465</issue>
            <fpage>88</fpage>
            <page-range>88-90</page-range>
            <pub-id pub-id-type="pmid">6251550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parsons</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Justice</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Basal extracellular dopamine is decreased in the rat nucleus accumbens during abstinence from chronic cocaine.</article-title>
            <source>Synapse</source>
            <year>1991</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-5</page-range>
            <pub-id pub-id-type="pmid">1796352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kosten</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Markou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koob</surname>
                <given-names>GF</given-names>
              </name>
            </person-group>
            <article-title>Depression and stimulant dependence: neurobiology and pharmacotherapy.</article-title>
            <source>J Nerv Ment Dis</source>
            <year>1998</year>
            <month>Dec</month>
            <volume>186</volume>
            <issue>12</issue>
            <fpage>737</fpage>
            <page-range>737-45</page-range>
            <pub-id pub-id-type="pmid">9865811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salloum</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Cornelius</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Daley</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Kirisci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Himmelhoch</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Thase</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.</article-title>
            <source>Arch Gen Psychiatry</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>62</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-45</page-range>
            <pub-id pub-id-type="pmid">15630071</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salloum</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Douaihy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cornelius</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kirisci</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Divalproex utility in bipolar disorder with co-occurring cocaine dependence: a pilot study.</article-title>
            <source>Addict Behav</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>410</fpage>
            <page-range>410-5</page-range>
            <pub-id pub-id-type="pmid">16814474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Nejtek</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Perantie</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Bobadilla</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Quetiapine in bipolar disorder and cocaine dependence.</article-title>
            <source>Bipolar Disord</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>406</fpage>
            <page-range>406-11</page-range>
            <pub-id pub-id-type="pmid">12519101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-29642.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Conner</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Gamble</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Bagge</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Swogger</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Houston</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Substance-induced depression and independent depression in proximal risk for suicidal behavior.</article-title>
            <source>J Stud Alcohol Drugs</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>75</volume>
            <issue>4</issue>
            <fpage>567</fpage>
            <page-range>567-72</page-range>
            <pub-id pub-id-type="pmid">24988255</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
